30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Seikagaku Posts Quarterly Revenue -

Seikagaku posted 1QFY16 revenue of ¥8.2BB (~US $80.5MM), +6.6% vs. the prior year.

  • Growth attributed in part to increase in overseas sales volume, which partially offset price reductions in Japan
  • ARTZ injectable increased on introduction of new syringes (reducing syringe breakage rate) and partner’s expansion of sales efforts
  • Gel-One single-injection increase also attributed to sales structure enhancement, while SUPARTZ FX 5-injection fell due to competition for multiple-injection products
  • Selecting U.S. sales partners for VISCO-3 three-injection hyaluronic acid product


Source: Seikagaku Corporation

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.